How Your Plasma Could Lead to a Potential Treatment for COVID-19

When you donate your plasma after recovering from COVID-19, you become the essential first step in a journey to develop a potential treatment for COVID-19. Even though no one can predict the results of clinical trials, here is a quick overview of the intended plan.

1. **PLASMA DONATION**
   Patients who have recovered from COVID-19 donate their plasma, which contains antibodies that could help the immune system fight the new coronavirus. The proteins found in plasma are the most important ingredients in making a potential treatment.

2. **PROCESSING**
   Convalescent plasma is sent to manufacturing facilities. There, it is pooled, processed to remove or inactivate viruses, and purified to create a “hyperimmune globulin” that contains a reliably consistent amount of antibodies.

3. **CLINICAL TRIALS**
   Once sufficient plasma is collected and processed, the potential treatment could begin testing as early as June. Clinical trials will study whether it safely and effectively treats people at risk for serious complications from COVID-19.

4. **APPROVAL**
   If regulatory bodies like the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) determine that the potential treatment is both safe and effective, it could be approved to treat patients at risk for serious complications from COVID-19. The Alliance is also discussing potential use across the world with other national health authorities.

5. **AVAILABILITY**
   Once manufactured and distributed, the potential treatment will be ready for use. The timing depends on many factors, but in the best-case scenario, it could be available this year, which would make it one of the earliest approved scalable treatment options.

The above infographic aims to provide potential plasma donors with a general overview of the biopharmaceutical development process so that they can better understand their role in it. It should not be construed as making any claims about any potential treatment, including the timeline for, and/or outcomes of, clinical trials and/or regulatory approval.
About the CoVIg-19 Plasma Alliance

In an effort to help fight against the COVID-19 pandemic, a new alliance was created in April 2020 to help develop a potential plasma-derived therapy for people at risk for serious complications from COVID-19.

The CoVIg-19 Plasma Alliance brings together world-leading plasma companies to work on the development of an investigational unbranded polyclonal anti-SARS-CoV-2 hyperimmune globulin medicine with the potential to treat patients who are at risk for serious complications from COVID-19.

The “I” and “g” in CoVIg-19 stand for immune globulin, which the CoVIg-19 Plasma Alliance will use to concentrate the antibodies into a potential medicine.

The Alliance, formed by CSL Behring and Takeda, also includes the leading-edge expertise of Biotest, BPL, LFB, and Octapharma. The Bill & Melinda Gates Foundation is providing advisory support. Microsoft is providing technology including the Alliance website and the Plasma Bot for donor recruitment. Experts from the Alliance are collaborating across key aspects such as plasma collection, clinical trial development, and product manufacturing.